AAV9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling

OBJECTIVE: Adeno-associated virus serotype 9 (AAV9) vectors provide efficient and uniform gene expression to normal myocardium following systemic administration with kinetics that approach steady state within 2–3 weeks. However, due to the delayed onset of gene expression, AAV vectors have not previ...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Konkalmatt, Prasad R., Wang, Feng, Piras, Bryan A., Xu, Yaqin, O’Connor, Daniel M., Beyers, Ronald J., Epstein, Frederick H., Annex, Brian H., Hossack, John A., French, Brent A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3729029/
https://ncbi.nlm.nih.gov/pubmed/23065925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jgm.2673
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares